Oppenheimer analyst Francois Brisebois maintained a Buy rating on Cybin (CYBN – Research Report) today and set a price target of $4.50. The company’s shares closed yesterday at $0.39.
Brisebois covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Avadel Pharmaceuticals, and Achieve Life Sciences. According to TipRanks, Brisebois has an average return of -9.7% and a 32.72% success rate on recommended stocks.
Cybin has an analyst consensus of Strong Buy, with a price target consensus of $5.13, implying a 1,210.01% upside from current levels. In a report released on January 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.
See the top stocks recommended by analysts >>
Based on Cybin’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.89 million. In comparison, last year the company had a GAAP net loss of $9.97 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cybin (CYBN) Company Description:
Using cutting-edge drug discovery platforms and drug delivery systems, Cybin develops psychedelic therapies to address the mental health crisis.
Read More on CYBN:
- Cybin: IM dosing of SPL028 produced robust, short-duration psychedelic effects
- Cybin anticipates end-of-Phase 2 meeting with FDA for CYB003 in Q1
- USPTO grants Cybin ‘robust’ patent protection for CYB003 program to treat MDD
- Cybin to discuss efficacy data for CYB003 for major depressive disorder
- Cybin initiated with a Buy at Alliance Global Partners
